Intravenous  ||| S:0 E:12 ||| NNP
Nicotine  ||| S:12 E:21 ||| NNP
Self-Administration  ||| S:21 E:41 ||| NNP
in  ||| S:41 E:44 ||| IN
Smokers ||| S:44 E:51 ||| NNS
:  ||| S:51 E:53 ||| :
Dose-Response  ||| S:53 E:67 ||| NNP
Function  ||| S:67 E:76 ||| NNP
and  ||| S:76 E:80 ||| CC
Sex  ||| S:80 E:84 ||| NNP
Differences  ||| S:84 E:96 ||| NNP
Sex  ||| S:96 E:100 ||| NN
differences  ||| S:100 E:112 ||| NNS
in  ||| S:112 E:115 ||| IN
the  ||| S:115 E:119 ||| DT
sensitivity  ||| S:119 E:131 ||| NN
to  ||| S:131 E:134 ||| TO
nicotine  ||| S:134 E:143 ||| NNS
may  ||| S:143 E:147 ||| MD
influence  ||| S:147 E:157 ||| VB
vulnerability  ||| S:157 E:171 ||| NN
to  ||| S:171 E:174 ||| TO
tobacco  ||| S:174 E:182 ||| NN
dependence ||| S:182 E:192 ||| NN
.  ||| S:192 E:194 ||| .
The  ||| S:194 E:198 ||| DT
goal  ||| S:198 E:203 ||| NN
of  ||| S:203 E:206 ||| IN
this  ||| S:206 E:211 ||| DT
study  ||| S:211 E:217 ||| NN
was  ||| S:217 E:221 ||| VBD
to  ||| S:221 E:224 ||| TO
investigate  ||| S:224 E:236 ||| VB
the  ||| S:236 E:240 ||| DT
dose-response  ||| S:240 E:254 ||| JJ
function  ||| S:254 E:263 ||| NN
for  ||| S:263 E:267 ||| IN
the  ||| S:267 E:271 ||| DT
reinforcing  ||| S:271 E:283 ||| NN
and  ||| S:283 E:287 ||| CC
subjective  ||| S:287 E:298 ||| JJ
effects  ||| S:298 E:306 ||| NNS
of  ||| S:306 E:309 ||| IN
intravenous  ||| S:309 E:321 ||| JJ
nicotine  ||| S:321 E:330 ||| NN
in  ||| S:330 E:333 ||| IN
male  ||| S:333 E:338 ||| JJ
and  ||| S:338 E:342 ||| CC
female  ||| S:342 E:349 ||| JJ
smokers ||| S:349 E:356 ||| NNS
.  ||| S:356 E:358 ||| .
Tobacco-dependent  ||| S:358 E:376 ||| JJ
subjects  ||| S:376 E:385 ||| NNS
( ||| S:385 E:386 ||| -LRB-
12  ||| S:386 E:389 ||| CD
male  ||| S:389 E:394 ||| NN
and  ||| S:394 E:398 ||| CC
14  ||| S:398 E:401 ||| CD
female ||| S:401 E:407 ||| NN
)  ||| S:407 E:409 ||| -RRB-
participated  ||| S:409 E:422 ||| VBD
in  ||| S:422 E:425 ||| IN
four  ||| S:425 E:430 ||| CD
experimental  ||| S:430 E:443 ||| JJ
sessions  ||| S:443 E:452 ||| NNS
in  ||| S:452 E:455 ||| IN
which  ||| S:455 E:461 ||| WDT
they  ||| S:461 E:466 ||| PRP
received  ||| S:466 E:475 ||| VBD
sample  ||| S:475 E:482 ||| JJ
infusions  ||| S:482 E:492 ||| NN
of  ||| S:492 E:495 ||| IN
saline  ||| S:495 E:502 ||| NN
and  ||| S:502 E:506 ||| CC
nicotine  ||| S:506 E:515 ||| NNS
( ||| S:515 E:516 ||| -LRB-
0.1 ||| S:516 E:519 ||| CD
,  ||| S:519 E:521 ||| ,
0.2 ||| S:521 E:524 ||| CD
,  ||| S:524 E:526 ||| ,
0.3 ||| S:526 E:529 ||| CD
,  ||| S:529 E:531 ||| ,
or  ||| S:531 E:534 ||| CC
0.4â€‰ ||| S:534 E:538 ||| CD
mg  ||| S:538 E:541 ||| CD
doses ||| S:541 E:546 ||| NNS
)  ||| S:546 E:548 ||| -RRB-
in  ||| S:548 E:551 ||| IN
a  ||| S:551 E:553 ||| DT
randomized  ||| S:553 E:564 ||| JJ
double-blind  ||| S:564 E:577 ||| JJ
crossover  ||| S:577 E:587 ||| JJ
design ||| S:587 E:593 ||| NN
.  ||| S:593 E:595 ||| .
During  ||| S:595 E:602 ||| IN
each  ||| S:602 E:607 ||| DT
session ||| S:607 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
subjects  ||| S:616 E:625 ||| NNS
first  ||| S:625 E:631 ||| RB
received  ||| S:631 E:640 ||| VBD
the  ||| S:640 E:644 ||| DT
sample  ||| S:644 E:651 ||| NN
infusions ||| S:651 E:660 ||| NN
,  ||| S:660 E:662 ||| ,
and  ||| S:662 E:666 ||| CC
heart  ||| S:666 E:672 ||| NN
rate  ||| S:672 E:677 ||| NN
( ||| S:677 E:678 ||| -LRB-
HR ||| S:678 E:680 ||| NNP
) ||| S:680 E:681 ||| -RRB-
,  ||| S:681 E:683 ||| ,
blood  ||| S:683 E:689 ||| NN
pressure ||| S:689 E:697 ||| NN
,  ||| S:697 E:699 ||| ,
and  ||| S:699 E:703 ||| CC
subjective  ||| S:703 E:714 ||| JJ
stimulatory ||| S:714 E:725 ||| NN
,  ||| S:725 E:727 ||| ,
pleasurable  ||| S:727 E:739 ||| NN
and  ||| S:739 E:743 ||| CC
aversive  ||| S:743 E:752 ||| JJ
responses  ||| S:752 E:762 ||| NNS
were  ||| S:762 E:767 ||| VBD
monitored ||| S:767 E:776 ||| VBN
.  ||| S:776 E:778 ||| .
Immediately  ||| S:778 E:790 ||| RB
following  ||| S:790 E:800 ||| VBG
the  ||| S:800 E:804 ||| DT
sample  ||| S:804 E:811 ||| NN
infusions ||| S:811 E:820 ||| NN
,  ||| S:820 E:822 ||| ,
subjects  ||| S:822 E:831 ||| NNS
self-administered  ||| S:831 E:849 ||| JJ
either  ||| S:849 E:856 ||| CC
nicotine  ||| S:856 E:865 ||| NNS
or  ||| S:865 E:868 ||| CC
saline  ||| S:868 E:875 ||| NN
in  ||| S:875 E:878 ||| IN
six  ||| S:878 E:882 ||| CD
double-blind  ||| S:882 E:895 ||| JJ
forced-choice  ||| S:895 E:909 ||| JJ
trials ||| S:909 E:915 ||| NNS
.  ||| S:915 E:917 ||| .
A  ||| S:917 E:919 ||| DT
sex  ||| S:919 E:923 ||| NN
by  ||| S:923 E:926 ||| IN
dose  ||| S:926 E:931 ||| NN
interaction  ||| S:931 E:943 ||| NNS
was  ||| S:943 E:947 ||| VBD
observed  ||| S:947 E:956 ||| VBN
in  ||| S:956 E:959 ||| IN
the  ||| S:959 E:963 ||| DT
nicotine  ||| S:963 E:972 ||| JJ
choice  ||| S:972 E:979 ||| NN
paradigm ||| S:979 E:987 ||| NN
.  ||| S:987 E:989 ||| .
Nicotine  ||| S:989 E:998 ||| JJ
self-administration  ||| S:998 E:1018 ||| JJ
rate  ||| S:1018 E:1023 ||| NN
was  ||| S:1023 E:1027 ||| VBD
negatively  ||| S:1027 E:1038 ||| RB
correlated  ||| S:1038 E:1049 ||| VBN
with  ||| S:1049 E:1054 ||| IN
nicotine  ||| S:1054 E:1063 ||| JJ
dose  ||| S:1063 E:1068 ||| NN
in  ||| S:1068 E:1071 ||| IN
males  ||| S:1071 E:1077 ||| NNS
( ||| S:1077 E:1078 ||| -LRB-
males  ||| S:1078 E:1084 ||| NNS
displayed  ||| S:1084 E:1094 ||| VBN
choice  ||| S:1094 E:1101 ||| NN
preference  ||| S:1101 E:1112 ||| NN
for  ||| S:1112 E:1116 ||| IN
low  ||| S:1116 E:1120 ||| JJ
doses  ||| S:1120 E:1126 ||| NNS
of  ||| S:1126 E:1129 ||| IN
nicotine  ||| S:1129 E:1138 ||| NN
over  ||| S:1138 E:1143 ||| IN
high  ||| S:1143 E:1148 ||| JJ
doses  ||| S:1148 E:1154 ||| NNS
of  ||| S:1154 E:1157 ||| IN
nicotine ||| S:1157 E:1165 ||| CD
) ||| S:1165 E:1166 ||| -RRB-
,  ||| S:1166 E:1168 ||| ,
but  ||| S:1168 E:1172 ||| CC
no  ||| S:1172 E:1175 ||| DT
significant  ||| S:1175 E:1187 ||| JJ
relationship  ||| S:1187 E:1200 ||| NN
between  ||| S:1200 E:1208 ||| IN
dose  ||| S:1208 E:1213 ||| NN
and  ||| S:1213 E:1217 ||| CC
choice  ||| S:1217 E:1224 ||| NN
preference  ||| S:1224 E:1235 ||| NN
was  ||| S:1235 E:1239 ||| VBD
evident  ||| S:1239 E:1247 ||| JJ
in  ||| S:1247 E:1250 ||| IN
females ||| S:1250 E:1257 ||| NNS
.  ||| S:1257 E:1259 ||| .
Relative  ||| S:1259 E:1268 ||| JJ
to  ||| S:1268 E:1271 ||| TO
placebo ||| S:1271 E:1278 ||| VB
,  ||| S:1278 E:1280 ||| ,
sample  ||| S:1280 E:1287 ||| NN
doses  ||| S:1287 E:1293 ||| NNS
of  ||| S:1293 E:1296 ||| IN
nicotine  ||| S:1296 E:1305 ||| JJ
increased  ||| S:1305 E:1315 ||| JJ
heart  ||| S:1315 E:1321 ||| NN
rate  ||| S:1321 E:1326 ||| NN
and  ||| S:1326 E:1330 ||| CC
blood  ||| S:1330 E:1336 ||| NN
pressure ||| S:1336 E:1344 ||| NN
,  ||| S:1344 E:1346 ||| ,
and  ||| S:1346 E:1350 ||| CC
induced  ||| S:1350 E:1358 ||| JJ
stimulatory ||| S:1358 E:1369 ||| NN
,  ||| S:1369 E:1371 ||| ,
pleasurable ||| S:1371 E:1382 ||| NN
,  ||| S:1382 E:1384 ||| ,
and  ||| S:1384 E:1388 ||| CC
aversive  ||| S:1388 E:1397 ||| JJ
subjective  ||| S:1397 E:1408 ||| JJ
effects ||| S:1408 E:1415 ||| NNS
.  ||| S:1415 E:1417 ||| .
Diastolic  ||| S:1417 E:1427 ||| JJ
blood  ||| S:1427 E:1433 ||| NN
pressure  ||| S:1433 E:1442 ||| NN
increased  ||| S:1442 E:1452 ||| VBD
dose  ||| S:1452 E:1457 ||| JJ
dependently  ||| S:1457 E:1469 ||| NN
in  ||| S:1469 E:1472 ||| IN
males ||| S:1472 E:1477 ||| NNS
,  ||| S:1477 E:1479 ||| ,
but  ||| S:1479 E:1483 ||| CC
not  ||| S:1483 E:1487 ||| RB
in  ||| S:1487 E:1490 ||| IN
females ||| S:1490 E:1497 ||| NNS
.  ||| S:1497 E:1499 ||| .
These  ||| S:1499 E:1505 ||| DT
findings ||| S:1505 E:1513 ||| NNS
,  ||| S:1513 E:1515 ||| ,
which  ||| S:1515 E:1521 ||| WDT
demonstrate  ||| S:1521 E:1533 ||| VBP
sex  ||| S:1533 E:1537 ||| NN
differences  ||| S:1537 E:1549 ||| NNS
in  ||| S:1549 E:1552 ||| IN
nicotine  ||| S:1552 E:1561 ||| JJ
self-administration  ||| S:1561 E:1581 ||| NN
for  ||| S:1581 E:1585 ||| IN
doses  ||| S:1585 E:1591 ||| NNS
that  ||| S:1591 E:1596 ||| WDT
are  ||| S:1596 E:1600 ||| VBP
near  ||| S:1600 E:1605 ||| JJ
to  ||| S:1605 E:1608 ||| TO
the  ||| S:1608 E:1612 ||| DT
reinforcement  ||| S:1612 E:1626 ||| NN
threshold ||| S:1626 E:1635 ||| NN
,  ||| S:1635 E:1637 ||| ,
suggest  ||| S:1637 E:1645 ||| VBP
that  ||| S:1645 E:1650 ||| DT
male  ||| S:1650 E:1655 ||| NN
and  ||| S:1655 E:1659 ||| CC
female  ||| S:1659 E:1666 ||| JJ
smokers  ||| S:1666 E:1674 ||| NNS
may  ||| S:1674 E:1678 ||| MD
respond  ||| S:1678 E:1686 ||| VB
differently  ||| S:1686 E:1698 ||| RB
to  ||| S:1698 E:1701 ||| TO
the  ||| S:1701 E:1705 ||| DT
changes  ||| S:1705 E:1713 ||| NNS
in  ||| S:1713 E:1716 ||| IN
nicotine  ||| S:1716 E:1725 ||| JJ
doses  ||| S:1725 E:1731 ||| NNS
available  ||| S:1731 E:1741 ||| JJ
for  ||| S:1741 E:1745 ||| IN
self-administration.Neuropsychopharmacology  ||| S:1745 E:1789 ||| CD
advance  ||| S:1789 E:1797 ||| NN
online  ||| S:1797 E:1804 ||| NN
publication ||| S:1804 E:1815 ||| NN
,  ||| S:1815 E:1817 ||| ,
3  ||| S:1817 E:1819 ||| CD
February  ||| S:1819 E:1828 ||| NNP
2016 ||| S:1828 E:1832 ||| CD
;  ||| S:1832 E:1834 ||| :
doi ||| S:1834 E:1837 ||| FW
: ||| S:1837 E:1838 ||| :
10.1038 ||| S:1838 E:1845 ||| CD
/ ||| S:1845 E:1846 ||| CD
npp.2015.373 ||| S:1846 E:1858 ||| CD
.  ||| S:1858 E:1860 ||| .
